Brii Biosciences Limited · HKEX:2137
Brii Biosciences — Investor Presentation (August 2024)
30 slides from Brii Biosciences's investor presentation, August 2024
Slide 1: Corporate Presentation
Stock Code: 2137.HK Corporate Presentation AUGUST 2024
Slide 2: Disclaimer
Disclaimer This presentation has been delivered for information purposes only and upon the express understanding that recipients of this presentation will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase sec
Slide 3: Who We Are
Who We Are Our Mission Our Focus Tackle public health challenges through Leading first-in-class and/or different-in-class breakthrough scientific innovation and treatment options across infectious diseases critical patient insights and central nervous system diseases High unmet Patients experience L
Slide 4: World-class Leadership Team with a Proven Track Record of Success
World-class Leadership Team with a Proven Track Record of Success Corporate Executive Team Susannah Cantrell Eleanor (Ellee) de Groot Zhi Hong Brian A. Johns Chief Business Officer Chief Technology Officer Chief Executive Officer Chief Scientific Officer Former COO and CBO at Second Former EVP of Op
Slide 5: Board of Directors and Strategic Advisors
World-class Leadership Team with a Proven Track Record of Success Board of Directors Zhi Hong Ankang Li Martin J. Murphy, Jr. Grace Hui Tang Yiu Wa Alec Tsui Gregg Huber Alton Taiyin Yang Executive Director Executive Director Independent Independent Independent Independent Independent Non-executive
Slide 6: Pipeline
Pipeline Indication Program Pre-clinical IND Phase 1 Phase 2 Phase 3 NDA/BLA Commercial Brii Rights Partners Infectious Disease Programs BRII-179 Global Greater Treatment(1) Elebsiran(2) China* Hepatitis B Greater Tobevibart(3) China* (4) APAC ex- Prevention PreHevbri Japan BRII-732 Global Internall
Slide 7: HBV: Prevention to Cure
HBV Prevention to Cure
Slide 8: China is the Largest Market for HBV Functional Cure
China is the Largest Market for HBV Functional Cure Large Addressable Patient Population High Unmet Need for New Therapy Options No new novel MoAs have been approved in over 20 years Number of HBV USD expected for the ~254M Infected People ~3.4B China HBV market by Current SOC consisting of NRTIs* o
Slide 9: The Natural History of Chronic HBV Infection is Complex
The Natural History of Chronic HBV Infection is Complex Leaving HBV Patients at Different Stages of Disease and Underlying Immune Impairment Active hepatitis, reactivation and hepatitis flares increase the risk for cirrhosis and Hepatocellular Carcinoma (HCC) HBeAg-positive HBeAg-negative (HBe-antib
Slide 10: Novel Combination Therapies May Lead to Higher Functional Cure Rates
Novel Combination Therapies May Lead to Higher Functional Cure Rates Across All HBV Patient Groups Antiviral and Immunomodulation are Critical Targets for Successful HBV Therapy Reduction of viral antigen / genomic products Goal of New Therapies – HBV Functional Cure: ✓ Sustained, undetectable serum
Slide 11: Brii Bio's Programs for HBV Functional Cure Focus on Unique Mechanisms of Action
Brii Bio’s Programs for HBV Functional Cure Focus on Unique Mechanisms of Action for Both Host and Viral Pathways Host Pathways Innate Immune Responses Adaptive Immune Responses Elebsiran (BRII-835) NK Cells, other Innate B Cells, CD4+, HBV Targeting siRNA Immune Cells CD8+ T Cells • Clinical PoM &
Slide 12: Each Mechanism of Action Has Proven Clinical Benefit in Chronic HBV
Each Mechanism of Action Has Proven Clinical Benefit in Chronic HBV Infected Patients siRNA(1): elebsiran bnAb(2): tobevibart Therapeutic vaccine(3): BRII-179 Anti-HBs Positive Patients Magnitude and breadth of restored HBV antigen-specific T cells post BRII-179 trt No. 0/5 6/10 3/9 6/12 4/12 Anti-H
Slide 13: Brii Bio's HBV Functional Cure: Combination Strategy
Brii Bio’s HBV Functional Cure: Combination Strategy Fastest for Scientific Potential Commercialization Differentiation Best-in-Class • Data from Vir’s Elebsiran + PEG- • Data from Elebsiran + • Upcoming data from Vir’s IFNα and our BRII-179 + PEG- BRII-179 study support MARCH Part B trial from IFNα
Slide 14: Brii Bio's HBV Functional Cure Program Highlights
Brii Bio’s HBV Functional Cure Program Highlights Late-breakers at APASL and EASL 2024 2H 2023 Program Summary • Long-term follow-up data of BRII-179 + PEG- • BRII-179 + PEG-IFNα Phase 2 (Late-breaker at AASLD 2023): IFNα combination with regard to HBsAg loss o At week 24 (EOT), compared to the plac
Slide 15: Leading the Path to Address HBV from Prevention to Cure
Leading the Path to Address HBV from Prevention to Cure ✓ Deep experience in HBV ✓ Experienced China team designing and executing HBV PoC studies in APAC and mainland China Prevention ✓ Access to large and heterogeneous HBV patient populations ✓ A broad clinical portfolio in HBV that enables multipl
Slide 16: Antibiotic Resistance
Antibiotic Resistance Mitigating a Major Public Health Threat
Slide 17: Increasing Antibiotic Resistance Drives a Critical Unmet Clinical Need in China
Increasing Antibiotic Resistance Drives a Critical Unmet Clinical Need in China Our Pipeline is Positioned to Address Unmet Needs for Gram- WHO Priority #1 List for New Drugs negative Bacterial Infections and NTM Lung Disease Indication Program Modality Positioning MDR/XDR gram- Potentially Best-In-
Slide 18: BRII-693 is a Potent and Safer New-Generation Polymyxin
BRII-693 is a Potent and Safer New-Generation Polymyxin • Very limited choices of antibiotics to treat carbapenem-resistant Acinetobacter spp. and P. aeruginosa, particularly for critical ill patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia • Polymyxin
Slide 19: HIV: Long-Acting Treatment Options
HIV Long-Acting Treatment Options
Slide 20: Daily Oral Market Expected to Shift to Long-Acting Options
Daily Oral Market Expected to Shift to Long-Acting Options as New Therapies Become Available Global Market Will Continue to Increase High Unmet Need for Long-Acting Therapy Options • Global HIV market reached $37.6 billion in 2020 • Developed markets, such as the United States, currently Patient Sur
Slide 21: Brii Bio is Developing Long-Acting Oral and Injectable Formulations of EFdA
Brii Bio is Developing a Long-Acting Oral and Injectable Formulations of EFdA to Combine with Other MoAs Building a Long-Acting HIV Therapy Portfolio NRTI: nucleoside reverse transcriptase inhibitor • BRII-753 is an injectable NCE in the BRII-753/732 NRTTI: nucleoside reverse transcriptase transloca
Slide 22: BRII-732 Pharmacokinetics Data Supports Further Development
BRII-732 Pharmacokinetics (PK) Data Supports Further Development as Part of Oral Weekly Combination Therapy ISL-TP PBMC Concentration Islatravir Plasma Concentration Following Single or Multiple Doses Following Multiple Oral Doses Time (hours) Time (hours) Time (hours) • After single or multiple ora
Slide 23: BRII-753 and BRII-732 are Ideal Cornerstones for Next Generation HIV Therapies
BRII-753 and BRII-732 are Ideal Cornerstones for Next Generation HIV Therapies Ideal Backbone for Once Weekly & Long-Acting Injectable Combinations: Capsid Inhibitor 3 2 1 OR BRII-753 MoAs Drugs Injection or + NNRTI OR Integrase Inhibitor NRTI, BRII-732, or Tablet Long- Acting BRII 732 OR NRTTI, Par
Slide 24: CNS: First-of-its-kind New Treatment Options
CNS First-of-its-kind New Treatment Options
Slide 25: The 1st Indication for CNS Pipeline will be PPD
The 1st Indication for CNS Pipeline will be PPD with Life Cycle Opportunities in Additional Anxiety and Depressive Disorders Brii Bio CNS Programs Extensive Lifecycle Opportunities • BRII-296 and BRII-297 are novel GABAA receptor positive allosteric modulators (PAMs) >264M people suffer from general
Slide 26: PPD is the Most Common Psychological Condition Impacting New Mothers
PPD is the Most Common Psychological Condition Impacting New Mothers, Limited Treatment Options Available Large Addressable Patient Population Highly Unmet Need for New Therapy Options is a mental health condition affecting mothers after • Until 2019 there were no pharmacological interventions PPD c
Slide 27: Restoring Normal Levels of GABAA Receptor Function Improves PPD Symptoms
Restoring “Normal” Levels of GABAA Receptor Function is Demonstrated to Improve PPD Symptoms Modulation of GABAA Receptor BRII-296 Restores Function Post-Partum Allopregnanolone (brexanolone) – a naturally occurring GABAA Receptor Binds to Novel PAM Binding Site neuroactive steroid that acts as a po
Slide 28: BRII-296 Pharmacokinetic Profile Enables Initiation of Phase 2 Study
BRII-296 Pharmacokinetic (PK) Profile Enables the Initiation of Phase 2 Clinical Study in PPD Patients BRII-296-001 clinical data BRII-296 Phase Cohort 16: 600mg1BRII-296 Clinicaladmix Datawith 80 BRII-296 Predicted Concentrations mg Depo-Medrol (2 inj, 300+40mg 3mL/inj) 100 Plasma Concentration (ng
Slide 29: BRII-296 will Redefine Treatment for PPD by Creating Patient Choice
BRII-296 will Redefine Treatment for PPD by Creating Patient Choice BRII-296, a novel GABAA receptor PAM, is a first-of-its-kind long-acting formulation of brexanolone, delivered as a single-injection therapy BRII-296 Value Proposition Zulresso Zuranolone SSRIs Treatment paradigm shift to single inj
Slide 30: Thank You!
Stock Code: 2137.HK Thank You!
Brii Biosciences — Investor Presentation (August 2024) on 6ix